|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.790 USD | +1.70% |
|
-5.29% | -80.18% |
| 07-16 | EnGene Therapeutics Initiates Planned BLA Submission For Detalimogene Voraplasmid And Provides Updates On LEGEND Phase 2 Trial | CI |
| 07-16 | Engene Therapeutics Inc. Announces Board Changes | CI |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +1.70% | -5.29% | +3.47% | -75.38% | -80.18% | -48.86% | -83.41% | - | - | 118M | |
| -0.81% | -0.33% | -0.55% | +12.86% | +38.44% | +27.15% | +81.12% | -19.55% | - | 55.23B | |
| +2.38% | -4.97% | -3.68% | +11.69% | +6.64% | +28.60% | +67.26% | +192.87% | +6,124.76% | 53.75B | |
| -0.11% | +0.86% | -0.21% | -10.25% | -2.47% | -15.63% | -13.56% | -71.72% | - | 23.48B | |
| -1.58% | -5.51% | -4.81% | -25.56% | -41.69% | -3.51% | +375.36% | +312.56% | +786.38% | 22B | |
| +2.49% | -0.92% | +8.03% | +12.09% | +23.22% | +20.31% | -12.15% | -68.01% | - | 19.78B | |
| -0.14% | -1.76% | +2.53% | +8.94% | -8.95% | +28.38% | -33.78% | -35.22% | +51.52% | 17.44B | |
| +0.58% | -5.88% | +3.46% | +4.95% | +23.36% | +16.30% | +540.37% | - | - | 14.66B | |
| +1.16% | +0.58% | +2.87% | +25.89% | +27.70% | +51.87% | +181.96% | +232.17% | +509.69% | 14.07B | |
| -5.09% | -10.87% | -15.15% | +72.01% | +141.92% | +153.11% | +272.20% | +1,301.97% | +585.75% | 13.02B | |
| -9.83% | -9.25% | -8.16% | -4.69% | -15.32% | +70.11% | +139.94% | +464.72% | +6,474.80% | 11.37B | |
| +1.28% | +0.62% | +7.13% | +18.84% | +31.53% | +456.00% | +148.56% | +26.02% | +1,365.10% | 12.3B | |
| +0.80% | -5.58% | -0.90% | -26.49% | -16.86% | -39.23% | +128.87% | +86.78% | - | 10.95B | |
| +2.60% | -1.83% | -5.60% | +25.72% | +26.57% | +122.28% | +141.86% | +170.96% | +623.20% | 10.92B | |
| +5.00% | -10.28% | -7.76% | -37.37% | -23.16% | -49.59% | +533.96% | +83.36% | +92.00% | 10.72B | |
| -0.30% | -0.02% | +123.49% | +115.65% | +79.66% | +186.11% | +345.08% | +365.13% | - | 8.82B | |
| +3.71% | +1.51% | +14.33% | +36.33% | +209.83% | +487.04% | +604.86% | -33.77% | -15.42% | 8.93B | |
| +2.96% | -1.74% | +2.12% | -16.71% | +13.54% | +35.57% | +85.16% | -18.09% | - | 7.93B | |
| -2.32% | -11.93% | +7.99% | +23.50% | +10.96% | +14.78% | +312.86% | +320.07% | - | 7.69B | |
| +5.62% | +0.58% | -3.73% | -2.24% | +21.28% | +60.71% | +19.83% | +158.12% | - | 8.08B | |
| Average | +0.50% | -2.76% | +6.24% | +8.49% | +23.30% | +80.08% | +191.82% | +192.69% | +1,659.78% | 16.56B | |
| Weighted average by Cap. | +0.38% | -1.39% | +2.61% | +10.38% | +22.30% | +60.68% | +160.02% | +153.45% | +2,637.51% |
- Stock Market
- Stocks
- ENGN Stock
- Sector enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
